Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
ParsIgene is a Tehran-based biotechnology company focused on the development and commercialization of molecular diagnostic solutions and genomic services. The company gained significant prominence for its production of high-sensitivity PCR kits for the detection of SARS-CoV-2 during the global pandemic. In addition to infectious disease diagnostics, ParsIgene offers comprehensive genetic testing services, including Whole Exome Sequencing (WES) and Whole Genome Sequencing (WGS), to assist in the diagnosis of rare genetic disorders and oncology. Their business model integrates the manufacturing of molecular biology reagents with clinical laboratory services to support personalized medicine initiatives. The company operates under international quality standards to provide reliable diagnostic tools to hospitals and research centers across the region.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Pars igene.